Needham analyst Michael Matson reiterated a Buy rating on SurModics (SRDX) on August 28 and set a price target of $68. The company’s shares closed last Monday at $47.06.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 7.0% and a 62.7% success rate. Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Cardiovascular Systems, and Zimmer Biomet Holdings.
SurModics has an analyst consensus of Moderate Buy, with a price target consensus of $66, implying a 39.2% upside from current levels. In a report issued on August 29, Barrington also maintained a Buy rating on the stock with a $64 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $82.35 and a one-year low of $38.06. Currently, SurModics has an average volume of 107.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
SurModics, Inc. engages in the provision of medical device and in vitro diagnostic technologies to the healthcare industry. It operates through the Medical Device and In Vitro Diagnostics segments.
